Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Reaffirmed by Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a report released on Friday morning, Benzinga reports. Piper Sandler currently has a $157.00 price objective on the biotechnology company’s stock.

Several other research firms have also commented on SRPT. Wedbush reissued an outperform rating and set a $224.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 29th. Robert W. Baird increased their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a research note on Friday. Oppenheimer raised shares of Sarepta Therapeutics from a market perform rating to an outperform rating and set a $180.00 target price for the company in a research note on Tuesday, May 14th. Bank of America increased their target price on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a buy rating in a research note on Friday. Finally, Cantor Fitzgerald reissued a neutral rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research note on Friday. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $177.65.

Sarepta Therapeutics Trading Up 30.1 %

Sarepta Therapeutics stock opened at $160.72 on Friday. The firm has a 50 day simple moving average of $125.56 and a 200-day simple moving average of $120.18. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The stock has a market capitalization of $15.19 billion, a PE ratio of 1,461.09 and a beta of 0.96. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business’s revenue was up 63.1% on a year-over-year basis. During the same period last year, the firm posted ($1.44) earnings per share. As a group, equities research analysts expect that Sarepta Therapeutics will post 2.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Principal Securities Inc. acquired a new position in shares of Sarepta Therapeutics during the 4th quarter worth $26,000. Mather Group LLC. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $28,000. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 125.0% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares during the last quarter. Cary Street Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 154.0% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 154 shares during the last quarter. Finally, New Covenant Trust Company N.A. acquired a new position in shares of Sarepta Therapeutics during the 1st quarter worth $32,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.